Verastem, Inc. cotiza a 8.25 USD y tiene una capitalización bursátil de $747M. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, which is an orally administered, small molecule dual RAF/MEK inhibitor developed to block MEK kinase activity and the …
| Periodo | 2026-11 | 2026-08 | 2026-05 | 2026-03 |
|---|---|---|---|---|
| Real | — | $-0.31 | $-0.43 | $-0.46 |
| Estimado | $-0.43 | $-0.45 | $-0.47 | $-0.50 |
| Sorpresa | — | +31.1% | +8.5% | +8.0% |
| Métrica | VSTM | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.0% | — |
| Operating Margin | -550.3% | -38.6% | -511.7% |
| Net Margin | -677.6% | -33.6% | -644.0% |
| FCF Margin | — | -13.9% | — |
| ROE | -366.2% | -40.4% | -325.8% |
| ROA | -85.0% | -32.0% | -53.0% |
| Current Ratio | 3.09 | 2.84 | +0.25 |
| Debt / Equity | — | 0.28 | — |